Headlines

Madrigal’s MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial
May 31, 2018

Madrigal Pharmaceuticals Reports 2018 First Quarter Financial Results and Reviews Key Clinical Achievements
May 8, 2018

Madrigal Pharmaceuticals Reports 2017 Fourth Quarter and Year-End Financial Results
March 13, 2018

Press Release History